Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01729884 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer
A Phase 2 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT01729884: Clinical Trial Phase 2 study, sponsored by University of Washington.
NCT01729884 is a Phase 2 study that was terminated before completion, run by University of Washington. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01729884, a Phase 2 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase II trial studies how well vaccine therapy works in treating patients with stage IV hormone receptor positive breast cancer. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells.
Primary Outcome
Wilson score 90% confidence intervals will be reported.
Interventions
- BIOLOGICAL HER-2/neu peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2012-12 |
| Phase | Phase 2 |
Why NCT01729884 stopped before completion
NCT01729884 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which HER-2/neu peptide vaccine is the first listed.
NCT01729884 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01729884 about?
NCT01729884 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer". This phase II trial studies how well vaccine therapy works in treating patients with stage IV hormone receptor positive breast cancer. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells.
What is the current status of trial NCT01729884?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2012-12.
What interventions are being tested in trial NCT01729884?
The interventions under investigation include: HER-2/neu peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01729884?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01729884's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia